{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:33:36Z","timestamp":1772127216618,"version":"3.50.1"},"reference-count":14,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,2,9]]},"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>We present a novel treatment protocol that was successful in the management of Hodgkin\u2019s-associated vanishing bile duct syndrome, a rare but serious complication of Hodgkin\u2019s lymphoma. We believe that publication of this treatment protocol and the rationale for its development will be of interest to anyone faced with treating this challenging condition.<\/jats:p>","DOI":"10.1136\/bcr-2018-227676","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T05:39:29Z","timestamp":1550813969000},"page":"bcr-2018-227676","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin\u2019s lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6854-5002","authenticated-orcid":false,"given":"Min","family":"Fong","sequence":"first","affiliation":[{"name":"Queensland Health, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Boyle","sequence":"additional","affiliation":[{"name":"Queensland Health, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naadir","family":"Gutta","sequence":"additional","affiliation":[{"name":"Haematology, Greenslopes Private Hospital, Greenslopes, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"key":"2025082710492201000_12.2.bcr-2018-227676.1","first-page":"90","article-title":"Celecoxib-induced cholestatic liver injury","volume":"1","author":"Judson","year":"2014","journal-title":"Case Rep Clin Pathol"},{"key":"2025082710492201000_12.2.bcr-2018-227676.2","first-page":"1038","article-title":"Cholestasis secondary to Hodgkin\u2019s disease: report of 2 cases of vanishing bile duct syndrome","volume":"83","author":"de Medeiros","year":"1998","journal-title":"Haematologica"},{"key":"2025082710492201000_12.2.bcr-2018-227676.3","doi-asserted-by":"publisher","DOI":"10.1080\/02841860701644078"},{"key":"2025082710492201000_12.2.bcr-2018-227676.4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.510260101","article-title":"Resolution of paraneoplastic bile duct paucity following successful treatment of Hodgkin\u2019s disease","volume":"26","author":"Crosbie","year":"1997","journal-title":"Hepatology"},{"key":"2025082710492201000_12.2.bcr-2018-227676.5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1157\/13074061","article-title":"[Ductal regeneration in vanishing bile duct syndrome in Hodgkin\u2019s lymphoma]","volume":"28","author":"C\u00f3rdoba Iturriagagoitia","year":"2005","journal-title":"Gastroenterol Hepatol"},{"key":"2025082710492201000_12.2.bcr-2018-227676.6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/1756-0500-7-529","article-title":"Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin\u2019s lymphoma: a case report and review of the literature","volume":"7","author":"Rota Scalabrini","year":"2014","journal-title":"BMC Res Notes"},{"key":"2025082710492201000_12.2.bcr-2018-227676.7","first-page":"1247","article-title":"Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer","volume":"60","author":"Perry","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"2025082710492201000_12.2.bcr-2018-227676.8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.69"},{"key":"2025082710492201000_12.2.bcr-2018-227676.9","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197401)33:1<19::AID-CNCR2820330107>3.0.CO;2-M"},{"key":"2025082710492201000_12.2.bcr-2018-227676.10","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1992.158"},{"key":"2025082710492201000_12.2.bcr-2018-227676.11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00255487","article-title":"The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination","volume":"8","author":"Van den Berg","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025082710492201000_12.2.bcr-2018-227676.12","doi-asserted-by":"publisher","DOI":"10.1177\/106002809202600311"},{"key":"2025082710492201000_12.2.bcr-2018-227676.13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.955.955","article-title":"Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma","volume":"118","author":"Younes","year":"2011","journal-title":"Blood"},{"key":"2025082710492201000_12.2.bcr-2018-227676.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-227676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:49:28Z","timestamp":1756316968000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-227676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,21]]},"published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1136\/bcr-2018-227676"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-227676","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}